Disease-related malnutrition in outpatients with systemic sclerosis

Caporali, Roberto; Caccialanza, Riccardo; Bonino, Claudia; Klersy, Catherine; Cereda, Emanuele; Xoxi, Blerina; Crippa, A; Rava, Maria Luisa; Orlandi, Margherita; Bonardi, C.; Cameletti, B.; Codullo, Veronica; Montecucco, Carlomaurizio

doi:10.1016/j.clnu.2012.02.010

Cited by 54 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The fibrotic change of the lower intestinal tract reduces the abilities to perform digestion and absorption. Overall, patients with SSc have problems with their nutritional status [22]. Owing to movement disturbances in the lower digestive tract, bowel movements tend to be stagnant.…”

Section: Systemic Sclerosismentioning

confidence: 99%

The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis

Shima

2019

Modern Rheumatology

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a connective tissue disease, the pathogenesis of which is thought to involve interleukin-6 (IL-6), an inflammatory cytokine. This is based on findings of its concentration in patient serum, the results of an IL-6 suppression experiment in an animal model, and the results of a pilot study using IL-6 receptor antibody. However, it appears that a number of factors are involved in the pathology of SSc depending on the state of disease progression. In addition, the degree of involvement of IL-6 differs depending on the difference of organs within particular severe symptoms. Based on the findings from measurements of patient serum, the influence of IL-6 on the pathogenesis of SSc is greater in patients at a relatively early phase of the disease and in patients with lung lesions. Interleukin-13 (IL-13) is one of pro-fibrotic factors, and it is afraid that SSc patients with higher IL-13 have already lost the influence of IL-6. Therefore, although a clinical trial using the anti-IL-6 receptor antibody tocilizumab is underway, it is important to recognize the state of SSc patients prior to selecting treatment.

show abstract

Section: Systemic Sclerosismentioning

confidence: 99%

The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis

Shima

2019

Modern Rheumatology

View full text Add to dashboard Cite

show abstract

“…Prevalence of malnutrition in SSc patients is estimated to be 15-58% [51,82,83]. Mortality is significantly increased in underfed SSc patients compared to patients with adequate nutritional intakes, whereas about 4% deaths are attributable to consequences of malnutrition [14,83].…”

Section: Malnutritionmentioning

confidence: 99%

Gastrointestinal Involvement in Systemic Sclerosis: Overview, Neglected Aspects, Malnutrition, Body Composition and Management

Oreská¹,

Tomčík²

2019

New Insights Into Systemic Sclerosis [Working Title]

View full text Add to dashboard Cite

Gastrointestinal tract (GIT) involvement is the most common internal organ manifestation and is present in up to 90% of patients with systemic sclerosis (SSc). Clinical manifestations can differ according to the part of the GIT affected, disease course and symptoms. A majority of the symptoms are caused by GIT dysmotility. Up to 8% of SSc patients develop several GIT symptoms, which increase the mortality. Although GIT involvement is rarely the direct cause of death, it can lead to several comorbidities including malnutrition and negative alterations of body composition. These factors have a negative impact on quality of life and increase the mortality. To date, the treatment is rather symptomatic. The pathogenesis of GIT involvement in SSc still remains to be clarified to improve the treatment approaches including intravenous immunoglobulins and microRNA interventions.

show abstract

“…Malnutrition is common in SSc and may be associated with progressive GIT involvement (16, 17). All SSc patients should be screened for malnutrition, but this may prove challenging as malnutrition may be multifactorial in origin and not reflective in simple markers such as serum albumin (18, 19).…”

Section: Patient Reported Outcome Measuresmentioning

confidence: 99%

Measuring response in the gastrointestinal tract in systemic sclerosis

Khanna

Nagaraja

Gladue

et al. 2013

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review Gastrointestinal tract (GIT) involvement in systemic sclerosis (scleroderma, SSc) is the most common internal complication. This review discusses the outcome measures to measure GIT involvement in clinical care and trials. Recent findings Patient-reported outcome measures have been validated (UCLA SCTC GIT 2.0 and NIH PROMIS® scales) in SSc-GIT. Multiple objective measures are available to assess mucosal involvement and motility in GIT. However, these need to validated in SSc for trials. Summary GIT is a common cause of morbidity and has negative impact on quality of life in SSc. Recommendations are given for trial design and evaluation of GI involvement in SSc.

show abstract

Disease-related malnutrition in outpatients with systemic sclerosis

Cited by 54 publications

References 29 publications

The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis

The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis

Gastrointestinal Involvement in Systemic Sclerosis: Overview, Neglected Aspects, Malnutrition, Body Composition and Management

Measuring response in the gastrointestinal tract in systemic sclerosis

Contact Info

Product

Resources

About